Hisato Takagi, Takuya Umemoto. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » AtorvastatinFluorobenzenes/therapeutic useHeart Failure/drug therapyHeart Failure/physiopathologyHeptanoic Acids/therapeutic useHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usePyrimidines/therapeutic usePyrroles/therapeutic useRandomized Controlled Trials as TopicRosuvastatin CalciumStroke Volume/drug effectsStroke Volume/physiologySulfonamides/therapeutic use
Substances: See more » FluorobenzenesHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrimidinesPyrrolesSulfonamidesRosuvastatin CalciumAtorvastatin
Year: 2011 PMID: 22200185 DOI: 10.1016/j.ijcard.2011.11.079
Source DB: PubMed Journal: Int J Cardiol ISSN: 0167-5273 Impact factor: 4.164